Novo Nordisk's High-Dose Wegovy Approvals in Europe — and What They Mean for UK Treatment

How the 7.2mg approval came about, and what the trial data actually showed

The STEP programme established semaglutide 2.4mg as an effective weight-management medicine, with the STEP 1 trial reporting an average body-weight reduction of around 15% over 68 weeks in adults with obesity, published in the New England Journal of Medicine. That figure held up across replications, but Novo Nordisk continued investigating whether a higher dose could extend results further.

The 7.2mg work answered that question clearly enough for regulators to act. Trials at this high dose of semaglutide reported roughly 20.7% average weight loss over 72 weeks, a substantial step up from the 2.4mg data and one that brings semaglutide much closer to the results seen with tirzepatide at its highest strength. Those figures drew from participants alongside structured lifestyle changes, as is standard in weight-management trials; isolated medicine effects are always smaller in real-world practice.

A common misconception is that a higher dose simply means taking more medicine from the start. The 7.2mg Wegovy pen is a maintenance target, not an entry point. Titration begins at 0.25mg and advances in roughly four-weekly steps under prescriber oversight; 7.2mg is where the journey can end, not where it begins. The MHRA's April 2026 approval announcement confirms the pen is designed for maintenance use only, with an auto-dosing mechanism and built-in covered needle that locks after use.

What the 7.2mg licence covers, and where its limits sit

The dedicated single-dose 7.2mg pen is licensed specifically for adults with a BMI of 30 or above for weight management. It does not extend to the cardiovascular-risk indication (which sits separately within the Wegovy licence) and is not approved for adults with a BMI below 30. That boundary matters: prescribers assess the full clinical picture rather than BMI alone, and suitability for reaching the high dose of Wegovy depends on how a patient tolerates and responds to earlier doses.

The broader Wegovy licence in the UK covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. On the NHS, access to Wegovy runs through specialist weight-management services under NICE's technology appraisal TA875, which specifies a maximum treatment duration of two years within a multidisciplinary programme, waiting lists are often long. For those who do not meet NHS criteria or prefer not to wait, private routes through a regulated, GPhC-registered pharmacy are available subject to clinical assessment.

Side effects across the semaglutide dose range are predominantly gastrointestinal: nausea, loose stools, constipation, reflux, and fatigue are the most frequently reported. These tend to be most noticeable in the early weeks and after each dose step, and our page on whether your Wegovy dose is too high can help you recognise when symptoms may warrant a conversation with your prescriber. A fuller picture of what to watch for at higher doses is set out on our high-dose Wegovy side effects page.

How 7.2mg fits into the broader landscape of high-dose weight-loss treatment in the UK

Before the 7.2mg pen, the main comparator at the high-efficacy end of the licensed market was tirzepatide 15mg (Mounjaro), whose dual GIP and GLP-1 receptor mechanism produced average weight reductions of around 20 to 21% in the SURMOUNT-1 trial across thousands of participants. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, showed tirzepatide producing greater average weight loss than semaglutide 2.4mg over 72 weeks. The 7.2mg data narrows that gap; whether it closes it entirely is a question the evidence does not yet fully settle, and head-to-head data at 7.2mg semaglutide versus tirzepatide 15mg remains limited.

For context on how Wegovy's dose schedule works across the whole range, our page on how high Wegovy dosage goes walks through each step. If you want to understand where the UK's licensed options sit relative to each other on cost, our Wegovy price comparison covers what private treatment typically involves. The right choice between medicines is always a clinical one, shaped by your health history, tolerance, and what a prescriber judges appropriate after a proper assessment.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers the same day, not software. If Wegovy is clinically suitable and you order before midday on a working day, treatment is dispatched the same day and arrives free the next working day via DPD. Details of our clinical team are on the clinical team page.

If you'd like to explore whether Wegovy or another licensed weight-management medicine could be right for you, check your eligibility with a free consultation.